logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
15-Feb-2019
Bausch Health Companies Inc.
BHC, BHC.TO
Resubmission of NDA for DUOBRII Lotion
Topical treatment of plaque psoriasis
Feb 2019
Cara Therapeutics Inc.
Preliminary results from pivotal phase III trial of KORSUVA injection (KALM-1)
Hemodialysis patients suffering from moderate-to-severe chronic kidney disease-associated pruritus
18-Jan-2019
TYME TECHNOLOGIES, INC.
Interim data from Stage 1 of phase II trial of SM-88
Pancreatic cancer
Q1 2019
TYME TECHNOLOGIES, INC.
Updated data from phase II trial of SM-88
Pancreatic cancer
Q1 2019
Unity Biotechnology, Inc.
Initial results from phase I clinical trial of UBX0101
Moderate to severe osteoarthritis of knee
after Q1 2019
Xeris Pharmaceuticals Inc
Results from phase I clinical trial of ready-to-use liquid glucagon
To test blood glucose in people with Type 1 Diabetes before and after exercise
after Q1 2019
Neon Therapeutics, Inc.
52-week data from phase 1b clinical trial of NEO-PV-01
Metastatic setting
after Q1 2019
Neon Therapeutics, Inc.
Submission of IND for NEO-SV-01
Subset of ER+ breast cancer
after Q1 2019
Aptinyx Inc
Top-line data from Phase 2 study of NYX-2925
Painful diabetic peripheral neuropathy
after Q1 2019
Aptinyx Inc
Top-line data from Phase 2 exploratory study of NYX-2925
Fibromyalgia
Q1 2019
Opiant Pharmaceuticals Inc.
Top-line data from phase II clinical trial of OPTN001 (naloxone nasal spray)
Bulimia Nervosa
2019
Y-mAbs Therapeutics, Inc.
Submission of BLA for Naxitamab
Pediatric patients with relapsed or refractory, high-risk neuroblastoma
2019
Y-mAbs Therapeutics, Inc.
Submission of BLA for Omburtamab
Pediatric patients with central nervous system leptomeningeal metastases from neuroblastoma
Q1 2019
Proteostasis Therapeutics, Inc.
Data from fourth dosing cohort in phase I study of combination therapy doublet of PTI-808 and PTI-801
Cystic fibrosis
Q1 2019
Esperion Therapeutics
Submission of NDA for bempedoic acid
low-density lipoprotein cholesterol LDL-C-lowering indications
Q1 2019
Esperion Therapeutics
Submission of NDA for bempedoic acid/ezetimibe combination pill
LDL-C-lowering indications
after Q1 2019
Melinta Therapeutics, Inc
Filing of sNDA for Baxdela
Community acquired bacterial pneumonia (CABP)
after Q1 2019
Axsome Therapeutics, Inc.
Top-line results from phase III trial of AXS-05
Treatment resistant depression(TRD )
after Q1 2019
Arcus Biosciences, Inc
Initial data from dose-escalation trials of AB928 + AB122 and AB928 + chemotherapy
Cancer
after Q1 2019
Arcus Biosciences, Inc
Report safety and pharmacokinetic data from phase I trial of AB680
Healthy volunteers
before Q1 2019
Axsome Therapeutics, Inc.
Top line results from phase II trial of AXS-05 (ASCEND)
Major depressive disorder
Q1 2019
Axsome Therapeutics, Inc.
Top line results from phase II trial of AXS-05
Smoking cessation treatment
after Q1 2019
Replimune Group Inc.
Filing of IND for RP2
Mixed advanced solid tumors
after Q1 2019
Acceleron Pharma, Inc
Submission of NDA for Luspatercept
Myelodysplastic syndromes and beta-thalassemia
after Q1 2019
FibroGen Inc.
Submission of NDA for Roxadustat
Chronic kidney disease anemia